Physician profile
Ann M Lepine
NPI 1447253471
$2,700.01
in general payments reported to CMS, 2019-2025
14 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $852 · 2022: $585 · 2023: $510 · 2024: $226 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,263.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $626.81 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $474.01 | 2021-2023 | Breztri |
| Janssen Pharmaceuticals, INC | $416.96 | 2021-2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $225.79 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $224.12 | 2021-2023 | Shingrix |
| Madrigal Pharmaceuticals | $143.64 | 2025 | Rezdiffra |
| Lilly USA, LLC | $123.46 | 2023-2025 | Zepbound, Mounjaro |
| Biohaven Pharmaceuticals, INC. | $119.27 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $113.51 | 2022-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $108.81 | 2022-2023 | Verquvo, Steglatro, Belsomra |
| Sun Pharmaceutical Industries INC. | $58.92 | 2021 | |
| Abbvie INC. | $32.64 | 2025 | |
| Dexcom, INC. | $18.17 | 2023 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $13.90 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Lepine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.